The Italian Journal of Neurological Sciences

, Volume 13, Issue 9, pp 723–728

AZT-induced mitochondrial myopathy

  • Tomelleri G. 
  • Tonin P. 
  • Spadaro M. 
  • Tilia G. 
  • Orrico D. 
  • Barelli A. 
  • Bonetti B. 
  • Monaco S. 
  • Salviati A. 
  • Morocutti C. 
  • Rizzuto N. 
Original Articles

Abstract

Histochemical, electron microscopy and biochemical studies were performed on muscle biopsy specimens from 11 AIDS patients treated with zidovudine. A peculiar association of structural abnormalities and mitochondrial dysfunction was found. Focal cytochrome c oxidase (COX) deficiency was evident in muscle sections from 9 patients, 8 of whom had received long-term treatment while one had been treated for 1 month only. Electron microscopy showed changes in number, size and structure of mitochondria. Biochemical studies proved partial COX and succinate cytochrome c reductase (SCR) deficiency in 4 patients; one patient had only reduced SCR activity. Our data confirm that AZT therapy can cause toxic myopathy with mitochondrial dysfunction.

Key Words

AIDS AZT mitochondrial myopathy cytochrome c oxidase succinate cytochrome c reductase type 2 fiber atrophy 

Sommario

Sono state esaminate le biipsie muscolari di 11 pazienti affetti da AIDS in trattamento con Zidovudina. Si è riscontrato una caratteristica associazione di anormalità strutturali delle fibre e di disfunzione mitocondriale.

Un deficit focale di citocromo c ossidasi (COX) era presente nelle sezioni muscolari di nove pazienti, otto dei quali avevano subito un trattamento di lunga durata, mentre uno era stato trattato solo per un mese.

La microscopia elettronica mostrava modificazioni della struttura, del numero e volume dei mitocrondri. Le indagini biochimiche hanno evidenziato un deficit parziale di COX e di succinato citocromo c reduttasi (SCR) di quattro pazienti, mentre in un paziente riduzione di attività della sola SCR. I nostri dati confermano che la terapia con AZT può causare una miopatia tossica con disfunzione dei mitocondri.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Anderson S., Bankier A.T., Barrell B.G. et al.:Sequence and organization of the human mitochondrial genome. Nature, 290:457, 1981.CrossRefPubMedGoogle Scholar
  2. [2]
    Arnaudo E., Dalakas M.C., Shanske S. et al.:Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet, 337:508–510, 1991.CrossRefPubMedGoogle Scholar
  3. [3]
    Bessen L.J., Greene J.B., Louie E. et al.:Severe poymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N. Engl. J. Med., 318:708, 1988.Google Scholar
  4. [4]
    Chalmers A.C., Greco C.M., Miller R.G.:Prognosis in AZT myopathy. Neurology, 41:1181–1184, 1991.PubMedGoogle Scholar
  5. [5]
    Collier A.N., Bozzette S., Coombs R.W. et al.:A pilot study of low-dose of zidovudine in human immunodeficiency virus infection. N. Engl. J. Med., 323:1015–1021, 1990.PubMedGoogle Scholar
  6. [6]
    Dalakas M.C., Pezeshkpour G.H., Gravell M., Seven J.L.:Polymyositis associated with AIDS retrovirus. JAMA, 256:2381–2383, 1986.CrossRefPubMedGoogle Scholar
  7. [7]
    Dalakas M.C.:Progressive nemaline (rod) myopathy associated with HIV infection. N. Engl. J. Med., 317:1602–1603, 1987.PubMedGoogle Scholar
  8. [8]
    Dalakas M.C., Pezeshkpour G.H.:Neuromuscular diseases associated with immunodeficiency virus infection. Ann. Neurol., 23 (suppl):S38-S48, 1988.CrossRefPubMedGoogle Scholar
  9. [9]
    Dalakas M., Wichman A., Sever J.:AIDS and the nervous system JAMA, 261:2396–2399, 1989.Google Scholar
  10. [10]
    Dalakas M.C., Illa I., Pezeshkpour G.H. et al.:Mitochondrial myopathy caused by long term zidovudine therapy. New Engl. J. Med., 322:1098–1105, 1990.PubMedGoogle Scholar
  11. [11]
    Di Mauro S., Servidei S., Zeviani M. et al.:Cytochrome c oxidase deficiency in Leigh Syndrome. Ann. Neurol., 22:498–506, 1987.CrossRefPubMedGoogle Scholar
  12. [12]
    Dubowitz V.:Muscle biopsy. A pratical approach. Balliere Tindall, London, 1985.Google Scholar
  13. [13]
    Fischl M.A., Richman M.H., Grieco M.H.:The efficacity of azitothimidine (AZT) in the treatment of patient with AIDS and AIDS-related complex. N. Engl. J. Med., 317:185–191, 1987.PubMedGoogle Scholar
  14. [14]
    Gabbai A.A., Schmidt B., Castelo A. et al.:Muscle biopsies in AIDS and ARC: analysis of 50 patients. Muscle and nerve, 13:541–544, 1990.CrossRefPubMedGoogle Scholar
  15. [15]
    Gertner E., Thurn J.R., Willons D.N. et al.:Zidovudine associated myopathy. Am. J. Med., 86:814–818, 1989.CrossRefPubMedGoogle Scholar
  16. [16]
    Gorard D.A., Henry K., Guiloff, R.J.:Necrotizing myopathy and zidovudine. Lancet i:1050, 1988.CrossRefGoogle Scholar
  17. [17]
    Helbert M., Fletcher T., Pedle B. et al.:Zidovudine associated myopathy. Lancet, ii:689–690, 1988.CrossRefGoogle Scholar
  18. [18]
    Jhonson M.A., Turnbull D.M., Dick D.J., Sherrat H.S.A.:A partial deficiency of cytochrome c oxidase in chronic progressive external ophthalmoplegia. J. Neurol. Sci., 60:31–53, 1983.CrossRefPubMedGoogle Scholar
  19. [19]
    Lange D.J., Britton C.B., Younger D.S., Hays A.P.:The neuromuscular manifestations of human immunodeficiency virus infections. Arch. Neurol., 45:1084–1088, 1988.PubMedGoogle Scholar
  20. [20]
    Mhiri C., Baudrimont M., Bonne G. et al.:Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol., 29:606–614, 1991.CrossRefPubMedGoogle Scholar
  21. [21]
    Mitshuya H., Weinhold K.I., Furman P.A. et al.:3′-azido-3′-deoxythimidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotrophic virus type III/Lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci., 82:7096–7100, 1985.PubMedGoogle Scholar
  22. [22]
    Nonaka I., Koga Y., Shikura K. et al.:Muscle pathology in cytochrome c oxidase deficiency. Acta neuropathol., 77:152–160, 1988.PubMedGoogle Scholar
  23. [23]
    Richman D.D., Fischl M.A., Grieco M.H. et al.:The toxicity of azidothimidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double blind placebo controlled trial. N. Engl. J. Med., 317:192–197, 1987.PubMedGoogle Scholar
  24. [24]
    Simpson D.M., Benderan A.N.:Human immunodeficiency virus-associated myopathy: analysis of 11 patients. Ann. Neurol., 24:79–84, 1988.CrossRefPubMedGoogle Scholar
  25. [25]
    Simpson D.M., Chin C.D., Keilbaugh S.A. et al.:Studies on the inhibition of mtDNA replication by 3′-azido 3′-deoxythimidine and other dideoxynucleoside analogs which inhibit HIV-1 replication. Biochem. Pharmacol., 38:1033–36, 1989.CrossRefPubMedGoogle Scholar
  26. [26]
    Stern R., Gold J., Di Carlo E.F.:Myopathycomplicating acquired immune deficiency syndrome. Muscle and Nerve, 10:318–322, 1987.CrossRefPubMedGoogle Scholar
  27. [27]
    Yamamoto M., Nonaka I.: Skeletal muscle pathology in chronic progressive external ophthalmoplegia with ragged red fibers. Acta Neuropathol., 76:558–563, 1988.CrossRefPubMedGoogle Scholar
  28. [28]
    Yarchoan R., Weinhold K.G., Lyerly H.K. et al.:Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS-related complex Lancet, 1:576–580, 1986.Google Scholar

Copyright information

© Masson Italia Periodici S.r.l. 1992

Authors and Affiliations

  • Tomelleri G. 
    • 1
  • Tonin P. 
    • 1
  • Spadaro M. 
    • 2
  • Tilia G. 
    • 2
  • Orrico D. 
    • 1
  • Barelli A. 
  • Bonetti B. 
    • 1
  • Monaco S. 
    • 1
  • Salviati A. 
    • 1
  • Morocutti C. 
    • 2
  • Rizzuto N. 
    • 1
  1. 1.Istituto di Neurologia Policlinico Borgo RomaUniversità di VeronaVerona
  2. 2.Istituto di Clinica delle Malattie Nervose e MentaliUniversità “La Sapienza”Roma

Personalised recommendations